Pharmacy Industry Newsletter
Get weekly insights on pharmacy billing, NDC updates, and revenue optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime.
Merck acquires Terns for $6.7B in oncology bet
PLUS: FDA approves rare disease therapies for Hunter syndrome and ovarian cancer, medical schools drop equity requirements
Pfizer's Lyme vaccine moves forward despite mixed data
PLUS: FDA expands Rhythm's obesity drug, Parkinson's med safety updates, and 22,000+ pharma job cuts in 2025
Lilly's triple-G obesity drug hits Phase 3 milestone
PLUS: Novo's high-dose Wegovy wins FDA approval, J&J's oral psoriasis pill clears regulatory hurdles, and NIH funding crisis deepens
Judge blocks RFK Jr. vaccine policy overhaul
PLUS: Oral GLP-1 pill shows promising weight loss results, GSK expands RSV vaccine, and White House pushes most-favored nation drug pricing
FDA Launches Unified Safety Surveillance System
PLUS: Lilly warns of impurities in GLP-1 knockoffs, commits $3B to China manufacturing, and MedPAC calls out Medicare Advantage overpayments
Vinay Prasad Exits FDA as Biotech Stocks Rally
PLUS: BioNTech founders launch new mRNA venture, Novo strikes Hims deal, and Vertex kidney drug succeeds in trial
Lilly bypasses insurers with employer GLP-1 program
PLUS: Moderna settles COVID vaccine patent fight for $2.25B, FDA cracks down on compounded weight loss drugs
CMS Halts Elevance Medicare Advantage Enrollment
PLUS: FDA approves Ascendis dwarfism drug, UniQure gene therapy setback, AI chatbot gets breakthrough status
Lilly's GLP-1 pill beats Novo's Rybelsus in Phase 3
PLUS: FDA faces Senate scrutiny on rare disease reviews, Sarepta CEO announces retirement, and Generate raises $400M in IPO
Novo's Obesity Drug Fails Against Lilly's Zepbound
PLUS: Gilead's $7.8B Arcellx buy, FDA's gene therapy roadmap, and Merck's oncology split
DOJ sues OhioHealth over anticompetitive contracts
PLUS: Grail's cancer test misses study goal, Supreme Court strikes down tariffs, and Vertex's CRISPR therapy rebounds
FDA reverses course on Moderna's flu vaccine review
PLUS: New standard for drug approvals, psilocybin heads to FDA, and Grail's cancer test setback
Digital Health Integration Transforms Modern Pharmacy Practice
PLUS: AI clinical tools gain traction, remote patient monitoring expands, and pharmacy apps reshape patient engagement
Harm reduction programs gain ADA legal protections
PLUS: AstraZeneca targets 25+ blockbusters by 2030, fentanyl smoking linked to fewer overdoses, Hims faces regulatory scrutiny
Biosimilar Adoption Surges as Patents Expire on Major Biologics
PLUS: New adalimumab biosimilar enters market, oncology biosimilar pipeline expands, and payer formulary shifts accelerate
New CMS Rules Reshape 340B Program Oversight for 2026
PLUS: Hospital outpatient drug spending surges, insulin pricing update, and pharmacy quality measure changes
Independent Pharmacies Fight Back Against PBM Practices
PLUS: FTC releases damning PBM report, state attorney general actions, and pharmacy coalition gains momentum
FDA Accelerates Generic Drug Approvals in Push for Lower Prices
PLUS: New compounding regulations proposed, telepharmacy expansion, and specialty drug pipeline update
CVS Health Restructuring Plan Shakes Up Retail Pharmacy Landscape
PLUS: Walgreens explores going private, generic drug pricing trends, and pharmacy technician shortage deepens
What's Ahead for Pharmacy in 2026: Trends and Predictions
PLUS: New year drug launches, reimbursement outlook, and technology trends to watch
Pharmacy Industry Year in Review: The Biggest Stories of 2025
PLUS: Top drug launches, regulatory milestones, and what shaped pharmacy practice this year
Medicare Part D Changes Bring Relief for Seniors' Drug Costs in 2026
PLUS: Pharmacy deserts expand, biosimilar Humira gains market share, and new antibiotic wins FDA approval
Eli Lilly's Weight-Loss Drug Expansion Signals New Era in Obesity Treatment
PLUS: Novo Nordisk supply chain update, pharmacy benefit reform advances, and CVS earnings surprise